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Background: Prostate cancer is one of the most common male cancers in Western countries and takes the third place in morbidity 
in Ukraine. It is a highly heterogeneous disease. Aim: To analyze relative expression levels of the TGFB1, IL1B, FOS, EFNA5, TAGLN, 
PLAU, and EPDR1 genes in malignant and non-malignant prostate tissues. Materials and Methods: Total RNA was isolated from 
16 prostate adenomas, 37 prostate adenocarcinomas, and 29 conventionally normal prostate tissues. To analyze relative gene expres-
sion levels the quantitative real-time polymerase chain reaction was performed. Results: The significant alterations in the relative 
expression levels were found in all analyzed sample groups for 4 genes: FOS, EFNA5, IL1B, and TGFB1. We have found that FOS and 
EFNA5 were more frequently overexpressed in carcinomas with Gleason score ≤ 7, compared with adenomas. On contrary, PLAU 
expression levels were decreased more frequently in prostate cancers, compared with conventionally normal tissues. Noteworthy, 
we found positive correlation between IL1B expression level and PSA (for patients with slight PSA increase, no more than 20.0 ng/ml). 
Conclusion: The EFNA5, FOS, IL1B, PLAU, and TGFB1 genes that showed significant expression alterations in prostate tumors, 
compared with conventionally normal prostate tissue, may play role in prostate cancer development and should be further investigated.
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Prostate cancer is t�e most frequently diagnosed 
male cancers in Western countries� taking t�e t�ird 
place in morbidity and t�e second place in mortality 
in Ukraine in t�e year ���4 [�� �]. Despite numerous 
studies t�at aimed to s�ed lig�t on t�e molecular mec�a-
nisms� underlying initiation and subsequent progression 
of prostate tumors� t�e precise mec�anism and factors 
stimulating t�e fast transition to metastatic cancer are 
not yet fully understood. One of t�e key factors of t�ese 
pitfalls is a �ig� level of �eterogeneity of t�is malignancy. 
Prostate cancer is c�aracterized by not only interpatient 
�eterogeneity [�]� but more t�an a �alf of malignant 
prostate tumor of one patient contains several disease 
focuses [4� 5]. T�ese biological differences result in t�e 
differential prostate cancer-specific mortality rates [6] 
and make selection of t�e appropriate t�erapy for pa-
tients t�e real c�allenge [�].
Earlier� we �ave analyzed t�e gene expression pat-
tern in t�e prostate cancer cell lines� using a quantitative 
real-time polymerase c�ain reaction �qPCR� microarrays� 
in order to find differentially expressed genes and deduce 
t�e possible signaling pat�ways� involved in transformation 
into androgen-independent type. T�e studied prostate 
cancer cell lines LNCaP� DU�45� and PC� s�owed dif-
ferent invasion and metastatic potential; LNCaP cells are 
androgen-dependent� w�ile PC� — androgen-indepen-
dent [8� �]. Based on results of t�ese experiments� t�e 
following genes� namely TAGLN� EFNA5� IL1B� PLAU, 
TGFB1� EPDR1� and FOS were selected to study t�e clini-
cal samples. T�ese genes are involved in different cellular 
pat�ways� EFNA5, TAGLN, and EPDR1� for example� play 
a role in cell-cell and cell-matrix ad�esion� t�at are dimin-
is�ed during tumor progression [��]. Additionally� TAGLN 
is involved in t�e p5� pat�way [��] and IL1B — in t�e 
NF-κB pat�way [��]. It was s�own t�at PLAU participates 
in t�e control on invasion and metastasis [��]. It was 
reported also� t�at TGFB1 could promote angiogenesis 
and t�e epit�elial to mesenc�ymal cell transition [�4]. T�e 
transcriptional factor FOS is involved in different cellular 
processes� including inflammation [�5].
In t�e present study we aimed to validate t�e pre-
viously obtained data and to analyze relative expres-
sion �RE� levels of t�e TGFB1� IL1B� FOS� EFNA5� 
TAGLN� PLAU, and EPDR1 genes in malignant and 
non-malignant prostate tissues.
MATERIALS AND METHODS
Tissue samples. Prostate adenoma and carcinoma 
tissue specimens from perip�eral zone� as well as con-
ventionally normal tissues �CNT� from opposite transi-
tional zone of prostate were collected after surgical re-
section of prostate tumors from patients at t�e Institute 
of Urology of National Academy of �edical Sciences 
of Ukraine and National Cancer Institute �Kyiv� Ukraine� 
and were immediately frozen in liquid nitrogen. In total� 
�6 samples of benign prostatic �yperplasia �adenoma� 
and �� adenocarcinoma samples were collected; 
among t�em �� samples were supplemented wit� t�e 
paired CNT �Table ��. Among adenocarcinoma samples 
t�ere were �� samples of Gleason score �Gl� ≤ � and 
�4 samples of Gl > �. Twenty-nine samples represented 
t�e stages I and II; eig�t samples were of t�e stages 
III and IV. T�e samples were collected in accordance 
wit� t�e Declaration of Helsinki and approved by t�e 
guidelines issued by t�e Et�ic Committee of t�e Institute 
of Urology and National Cancer Institute� Kyiv� Ukraine. 
Also� all patients gave written informed consent.
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Table 1. Clinical and pathological characteristics of prostate samples and 
the total prostate-specific antigen (PSA) levels in blood serum of patients
Paired carcinoma samples Paired carcinoma samples
№ TNM Stage Gl PSA, ng/ml № TNM Stage Gl
PSA, 
ng/ml
1 T1сNxM0 І 7 8.19 20 T2сNxM0 ІІ > 7 90.00
2 T2aNxM0 ІІ 7 9.30 21 T2cNxM0 ІІ < 7 25.20
3 T2aNxM0 ІІ > 7 7.13 22 T2cNxM0 ІІ > 7 13.30
4 T2aNxM0 ІІ 7 18.60 23 T2сNxM0 ІІ > 7 84.20
5 T2aNxM0 ІІ 7 11.70 24 T3bNxM0 III > 7 106.00
6 T2аNхM0 ІІ 7 5.60 25 T3bNxM0 III > 7 51.00
7 T2аN0M0 ІІ > 7 37.80 26 T3bNхM0 ІІІ 7 53.00
8 T2bNxM0 ІІ 7 13.90 27 Т3bNхМ0 III < 7 23.57
9 T2bNxM0 ІІ < 7 6.50 28 T3bNxM0 ІІІ > 7 20.90
10 T2bNxM0 ІІ > 7 33.00 29 T2сN0M1 IV > 7 22.60
11 T2bNxM0 ІІ 7 6.92 Unpaired carcinoma samples
12 T2bN0M0 ІІ 7 5.03 1 T1cN0Mx II < 7 9.40
13 T2сNxM0 ІІ > 7 20.29 2 T2N0M0 II < 7 8.34
14 T2сNxM0 ІІ 7 19.27 3 T2N0M0 II < 7 25.24
15 T2сNxM0 ІІ > 7 25.08 4 T2N0M0 II < 7 3.80
16 T2сNxM0 ІІ 7 19.80 5 T2bN0M0 II 7 11.45
17 T2сNxM0 ІІ < 7 27.30 6 T2сN0M0 II 7 17.00
18 T2сNxM0 ІІ < 7 29.08 7 T3NxMx III > 7 –
19 T2сNxM0 ІІ > 7 17.00 8 T3aNxM0 ІІI 7 –
Isolation of the total RNA. Total RNA samples 
from t�e frozen tissues were isolated� using TRI Re-
agent �Sigma-Aldric�� USA�� according to t�e manu-
facturer’s instructions. T�e quality of t�e total RNA was 
assessed� using electrop�oresis; purity was analyzed� 
using t�e NanoDrop ���� spectrop�otometer �T�ermo 
Fis�er Scientific� USA�. RNA was stored t�en at �8� °C.
Synthesis of the first strand cDNA. T�e isolated 
total RNA was treated wit� DNAse I �T�ermo Scientific� 
USA�. cDNA was synt�esized from � µg of total RNA� us-
ing t�e RevertAid H �inus First Strand cDNA Synt�esis 
kit �T�ermo Scientific� USA�. All procedures were per-
formed� according to t�e manufacturer’s instructions.
Quantitative real-time PCR. qPCR was performed� 
using t�e �axima SYBR Green/ROX qPCR �aster �ix 
�T�ermo Scientific� USA� and CFX�6 Touc� Real-time 
PCR Detection System �Bio-Rad� USA�� according 
to t�e manufacturer’s instructions. T�e following condi-
tions were used: initial denaturation at �5 °C for �� m� 
followed by 4� cycles of denaturation at �5 °C for �5 s� 
annealing at 6� °C for �� s� and extension at �� °C for 
�� s. Primers used in qPCR are s�own in Table �. All data 
were analyzed� using qRT-PCR Data Analysis Software 
�Bio-Rad� USA�. T�is integrated web-based software 
package automatically calculates ��ΔΔCt-based relative 
quantities from t�e uploaded raw t�res�old cycle data. 
T�e TBP gene was used as a reference gene [�6]. T�e 
inter-run calibration was used to correct run-to-run 
differences. As calibrator� a mixture of two cDNA from 
adenoma samples was used. T�e Livak met�od ��ΔΔCt 
of calculation of gene RE was used. Specific amplifica-
tion was confirmed� using t�e melting curve met�od.
Statistical analysis. T�e Kolmogorov — Smirnov 
and Lilliefors tests were used for assessing normal-
ity of distribution for levels of RE. Contingency tables 
were used for assessment of association of RE levels 
in groups of adenomas� CNT� and carcinomas wit� t�e 
Gl and levels of t�e PSA. T�e permutation based Fis�-
er’s exact test was used for estimation of significance. 
T�e Wilcoxon test was used to analyze differences 
in RE levels between carcinomas and matc�ed CNT. Lo-
gistic regression was used to analyze associations be-
tween RE levels and clinical data of patients. p-values 
< �.�5 were considered as t�e statistically significant 
[��]. All statistical procedures were performed� using 
t�e STATISTICA ��.� software �StatSoft� USA� and also 
t�e Open Source Epidemiologic Statistics for Public 
Healt� �available at �ttp://www.openepi.com/�. Also 
t�e software ORIGIN 8.5 �OriginLab� USA� was used.
RESULTS
Levels of RE of t�e EFNA5� EPDR1� FOS� IL1B� PLAU� 
TAGLN� TGFB1 genes in comparison wit� TBP were as-
sessed in all t�e samples �Fig. ��. In group of patients wit� 
adenomas a median age was 66.5 years� in t�e range 
6���� years. In group of patients wit� adenocarcinomas 
median age was 6� years� in t�e range 48�8� years. For 
RE values descriptive statistics was performed �Fig. ��. 
We observed abnormal distributions in RE for all genes� 
except FOS� TAGLN, and EPDR1 in carcinomas and for 
IL1B in CNT� according to Kolmogorov — Smirnov and 
Lilliefors analysis. �oreover� we found t�at mean and me-
dian values of RE of TAGLN� EFNA5, and EPDR1 genes 
in adenomas were quite similar. Notewort�y� RE of all 
t�e genes s�owed t�e �ig� level of dispersion in adeno-
mas� carcinomas� and CNT: for example� range of FOS 
RE in CNT was �.��8��85.8��. Besides t�at� standard 
deviation values of t�e RE of t�e all genes in CNT� carcino-
ma and adenoma groups were quite �ig�. For example� 
RE of t�e FOS gene was even �ig�er t�an values of me-
dians: �E = �.�8� in carcinomas� w�ile SD = ��.6��.
To analyze t�e possible association of RE levels 
in different prostate tumors wit� contingency tables� 
RE levels and clinical data were divided into nominal 
meanings. T�us� RE levels were divided into � nominal 
meanings: �st — wit�out alterations �RE levels were 
in t�e range �.4���.���� �nd — wit� decreased RE 
�RE ≤ �.4� and �rd — wit� increased RE �RE ≥ �.��. 
Contingency table was created� w�ere in t�e rows t�ere 
are nominal meanings of RE and in t�e columns t�ere 
are nominal meanings of groups �Table ��.
It is well accepted t�at Gl is used for t�e classification 
of prostate cancers. As described in t�e European Associa-
tion of Urology guidelines� patients wit� localized or locally 
advanced prostate cancer wit� Gl �ig�er t�an � are in t�e 
group of a �ig�-risk of recurrence [�8]. Because of t�at� 
Table 2. Sequences of qPCR primers
Gene name Accession number Forward primer Reverse primer Amplicon length, bp
EFNA5 NM_001962 5´-CTGGATGTGTGTGTTCAGCC-3´ 5´-ATGGTAGTCACCCCTCTGGA-3´ 106
EPDR1 NM_017549 5´-CTGCTTTCAGGACACTCATC-3´ 5´-GCTGGCATTCTTCACTCTAC-3´ 146
FOS NM_005252 5´-CTACCACTCACCCGCAGACT-3´ 5´-GTGGGAATGAAGTTGGCACT-3´ 102
IL1B NM_000576 5´-GAAGCTGATGGCCCTAAACA-3´ 5´-AAGCCCTTGCTGTAGTGGTG-3´ 110
PLAU NM_002658 5´-CACACACTGCTTCATTGATTAC-3´ 5´-CCACCTCAAACTTCATCTCC-3´ 104
TAGLN NM_001001522 5´-AAGAATGATGGGCACTACCG-3´ 5´-ACTGATGATCTGCCGAGGTC-3´ 186
TGFB1 NM_000660 5´-CCCTGGACACCAACTATTGC-3´ 5´-CTTCCAGCCGAGGTCCTT-3´ 92
TBP NM_003194 5´-TGCACAGGAGCCAAGAGTGAA-3´ 5´-CACATCACAGCTCCCCACCA-3´ 132
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Fig. 1. RE in adenomas �lig�t blue color�� carcinomas �red color�� and CNT �green color� for genes: a� TAGLN� b� EFNA5� c� IL1B� 
d� PLAU� e� TGFB1� f� EPDR1� and g� FOS
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we created t�e contingency table� w�ere in t�e rows 
t�ere are t�e nominal meanings of RE and in t�e columns 
t�ere are nominal meanings of carcinoma samples wit� 
Gl ≤ � �n = ��� and > � �n = �4� �Table 4�. We analyzed t�e 
RE in t�e paired carcinoma samples� compared wit� CNT 
in order to find associations in groups wit� different nomi-
nal meanings of Gl. T�erefore� we used t�e contingency 
table� w�ere in t�e rows t�ere are t�e nominal meanings 
of RE and in t�e columns t�ere are t�e nominal meanings 
of carcinoma samples wit� Gl ≤ � �n = �4� and > � �n = �5�. 
T�e contingency table was generated in order to analyze 
associations in RE levels in t�e group of carcinomas com-
pared wit� CNT and levels of t�e PSA. In t�e rows t�ere 
are t�e meanings of RE and in t�e columns t�ere are t�e 
nominal meanings of t�e PSA levels: �st — wit� low increase 
of PSA level �n = �5� range 5.�����.��� and �nd — wit� �ig� 
increase of PSA level �n = �4� range ��.����6.��. We do not 
s�ow t�ese tables� because no significant alterations 
in analyzed groups were found.
Based on t�e analysis of t�e data presented in Table �� 
we found 4 genes: FOS �p = �.������ EFNA5 �p = �.������ 
IL1B �p = �.��8��� and TGFB1 �p = �.����� t�at s�ow sta-
tistically significant alterations in frequencies of samples 
wit� altered RE between adenomas� carcinomas� and 
CNT. T�e significant c�anges were observed between 
adenomas and carcinomas in RE of FOS �p = �.���6� and 
EFNA5 �p = �.��4��. �oreover� we found RE alterations be-
tween carcinomas and CNT for TGFB1 gene �p = �.�����. 
Also we found alterations w�en comparing adenomas 
and CNT in RE of t�e FOS �p = �.���5�� IL1B �p = �.��6��� 
TGFB1 �p = �.��8��� and EFNA5 �p = �.��84� genes. 
Notewort�y� after t�e analysis of t�e Table 4 data� no differ-
ences in frequencies of samples wit� altered RE in nominal 
meanings wit� different Gl was found. However� t�e FOS �p 
= �.���4� and EFNA5 �p = �.����� genes s�owed altered 
RE between carcinomas and ade nomas. Particularly� t�ere 
were differences between adenomas and carcinomas wit� 
t�e Gl ≤ � �FOS p = �.����� EFNA5 p = �.���4�.
It is well known� as we mentioned already� t�at pros-
tate cancer is �ig�ly �eterogeneous genetically and 
also� tumor even in patient could be multifocal [��]. T�e 
molecular nature of suc� �eterogeneity is still not c�arac-
terized. T�erefore� it is important to s�ow any differences 
between tumor and CNT derived from t�e same prostate. 
As one of factors t�at may vary� we �ave c�osen t�e gene 
RE levels. We compared t�e RE values in t�e paired carci-
noma — CNT samples� using t�e Wilcoxon test� and found 
t�e differential RE of t�e PLAU �p = �.��88� gene. Con-
sequently� we calculated t�e RE fold c�ange in t�e paired 
carcinoma —CNT samples. T�e fold c�ange two or more 
times was considered as significant [��]. We found t�at 
RE was decreased in ��.6% of carcinomas compared 
wit� CNT� w�ile RE was increased in 6.�% of samples for 
TGFB1; ��.6% and ��.�%� respectively� — for IL1B; ��.8% 
and �4.�% — for FOS; ��.�% and 6.�% — for EFNA5; 
�4.5% and �4.�% — for TAGLN; ��.�% and ��.�% — for 
PLAU� and ��.�% and ��.8% — for EPDR1.
We did not find any statistically significant asso-
ciations� using t�e permutation Fis�er’s exact test in t�e 
RE levels between carcinomas and CNT and Gl� nor did 
we found for RE and levels of t�e PSA. �oreover� we did 
not find correlations between mentioned above groups� 
using t�e Spearman test. However� we found moder-
ate direct correlations between all genes� except FOS 
��.4���.6��. In patients wit� t�e slig�t increase of t�e PSA 
levels �no more t�an ��.� ng/ml� we found t�e positive 
correlation between RE of IL1B gene and PSA level �non-
parametric regression analysis: OR = �.�; p = �.�����.
DISCUSSION
We observed a �ig� level of dispersion of t�e RE values 
for all t�e genes in all analyzed groups. It could be due 
to genetic �eterogeneity t�at takes place not only in pros-
Table 3. The contingency tables of RE levels in adenomas’, carcinomas’ 
and CNTs’ groups. Significance was calculated, using the permutation 
based Fisher’s exact test
Gene RE levels
Number of samples with relevant RE changes
Group
Adenoma (n = 16) Carcinoma (n = 37) CNT (n = 29)
TGFB1 I 9 24 27
II 62 93 12, 3
III 1 43 13
IL1B I 6 18 11
II 62 5 12
III 42 14 172
FOS I 5 1 0
II 2 1 0
III 91, 2 351 292
EFNA5 I 12 10 8
II 11 101 3
III 31, 2 171 182
TAGLN I 9 13 12
II 7 21 15
III 0 3 2
PLAU I 12 17 13
II 1 9 5
III 3 11 11
EPDR1 I 12 21 22
II 3 14 6
III 1 2 1
Note: RE levels: I — 0.41–2.09, II — ≤ 0.4, III — ≥ 2.1; 1 — significant changes 
between adenomas and carcinomas; 2 — significant changes between adeno-
mas and CNT; 3 — significant changes between carcinomas and CNT. In bold 
numbers marked sample frequencies with significant changes in groups.
Table 4. The contingency tables of RE levels in adenomas’ group and car-
cinomas’ groups with different Gl. Significance was calculated, using the 
permutation based Fisher’s exact test
Gene RE levels
Number of samples with relevant RE changes
Group
Adenoma (n = 16) Carcinoma Gl ≤ 7 (n = 23)
Carcinoma Gl > 7 
(n = 14)
TGFB1 I 9 14 10
II 6 7 2
III 1 2 2
IL1B I 6 11 7
II 6 3 2
III 4 9 5
FOS I 5 0 1
II 2 1 0
III 91 221 13
EFNA5 I 12 4 6
II 11 81 2
III 31 111 6
TAGLN I 9 8 5
II 7 13 8
III 0 2 1
PLAU I 12 9 8
II 1 5 4
III 3 9 2
EPDR1 I 12 13 8
II 3 8 6
III 1 2 0
Note: RE levels: I — 0.41–2.09, II — ≤ 0.4, III — ≥ 2.1; 1 — significant chan-
ges between adenoma and carcinoma samples with Gl ≤ 7. In bold numbers 
marked sample frequencies with significant changes in groups.
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Fig. 2. RE in t�e t�ree sample groups� namely adenomas 
�red color�� carcinomas �green color�� and CNT �blue color� 
for genes: a� TAGLN� b� EFNA5� c� IL1B� d� PLAU� e� TGFB1� 
f� EPDR1� and g� FOS. T�e data are presented as box plots� 
w�ere t�e bottom and top rectangles define t�e first and t�ird 
quartile� respectively. T�e line across t�e box is t�e median. 
T�e w�iskers represent minimum and maximum and outliers 
are depicted by asterisks
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tate cancers� but also in adenomas and CNT. Probably� t�e 
investigated genes are differently regulated at t�e differ-
ent conditions� w�ic� may depend on individual �ormonal 
state. Also� t�is mig�t be due to a complex mixture of cell 
pulls t�at differ not only by t�e origin �stromal and epit�e-
lial�� but also by various stages of progression in individual 
samples [��]. T�us� t�e �istological tissue analysis prior 
experimental part assessing gene expression� is crucial 
and very important. As was discussed above� we found 
significant differences of RE levels for a set of genes� 
namely FOS� EFNA5� IL1B, and TGFB1, w�en compared 
samples of adenomas� carcinomas� and CNT.
RE of FOS was increased frequently in carcinomas 
��5 out of ���� compared wit� adenomas �� out of �6� and 
in all CNT� compared wit� adenomas �� out of �6�. T�is 
mig�t suggest t�at t�e FOS proto-oncogene is activated 
in carcinomas. It is known t�at Fos is a subunit of t�e 
AP-� transcription factor [��]. Overexpression of FOS was 
found in ovary tumors [��] and osteosarcomas [�4]. T�is 
was associated wit� an advanced clinical stage and poor 
disease prognosis� as a rule. Contrary to mentioned above� 
t�e FOS gene was involved in growt� in�ibition of carcino-
ma cells [�5]� due to triggered apoptosis [�6]. �oreover� 
FOS expression was lower in cancer associated prostate 
fibroblasts� compared wit� �yperplastic ones [��]. Ac-
cording to our results� t�e possible FOS activation in CNT 
could be due to t�e tumor impact on surrounding tissues; 
alternatively� it is due to t�e mixture of normal and cancer 
cells in CNT. Increased RE of EFNA5 was observed more 
frequently in carcinomas ��� out of ���� compared wit� 
adenomas �� out of �6�. Similar results were observed 
in CNT ��8 out of ���� compared wit� adenomas �� out 
of �6�. T�is gene encodes ep�rin-A5. It is a member of t�e 
ep�rin gene family� w�ic� plays role in cell ad�esion [�8]. 
It was s�own t�at EFNA5 was decreased in c�ondrosar-
comas [��] and gliomas� compared wit� normal tissues. 
It acts as a tumor suppressor in gliomas� regulating nega-
tively t�e epidermal growt� factor receptor [��]. Hence� 
t�e increased RE of EFNA5 in carcinomas points out t�e 
possible activation of EFNA5 associated signaling pat�-
way� leading to subsequent aberrations in cell ad�esion 
in adenomas and carcinomas.
T�e increased RE levels of t�e IL1B gene were more 
frequently detected in CNT ��� out of ��� compared 
wit� adenomas �4 out of �6�. It may be due to general 
inflammation in prostate gland t�at is often associated 
wit� carcinogenesis. T�e similar tendency �but not 
significant� was found in carcinomas ��4 samples from 
��� compared wit� adenomas �4 samples from �6� t�at 
supports our �ypot�esis. Our data suggest t�at t�e 
�ig�er PSA levels �but no more t�an ��.� ng/ml� cor-
related wit� increased RE of t�e IL1B gene. According 
to our results� t�e prostate cancer patients s�owing 
increased IL1B RE levels may be at t�e intermediate 
risk for bioc�emical recurrence� as described in t�e 
guidelines of t�e European Association of Urology.
At t�e ot�er �and� IL1B encodes one of t�e pro- 
inflammatory interleukins t�at is usually elevated in pros-
tatic secretions of t�e patients wit� t�e c�ronic prostati-
tis [��]. It may be a valuable marker of inflammation in be-
nign prostate �yperplasia [��]. T�us� furt�er investigations 
on a larger group of adenomas s�ould be performed. Our 
results support an idea t�at t�e NF-κB signaling pat�way 
is activated in bot�� carcinomas and in CNT� because IL1B 
is one of activators of t�e NF-κB pat�way [��].
RE levels of TGFB1 were diminis�ed in adenomas more 
frequent �6 out of �6� t�an in CNT �� out of ���. Also� RE al-
terations �bot�� increase and decrease� was found more 
frequently in carcinomas ��� out of ��� compared wit� CNT 
�� out of ���. T�is gene encodes t�e transforming growt� 
factor beta �� regulating cell differentiation� proliferation� 
migration� and apoptosis [�4]. It plays t�e opposite roles 
in different types of prostate tumors: it acts as a growt� 
in�ibitor in normal tissues and early stage tumors [�5] and 
as a promoter in advanced prostate cancers [�6]. T�e op-
posite direction of alterations in RE levels of TGFB1 in car-
cinomas compared wit� CNT could be due to variations 
of individuals� reflecting different stages of disease. T�e 
similar c�anges in RE of t�e FOS� EFNA5, and IL1B genes 
in carcinomas and CNT could be due to �eterogeneity 
of bot�� cancers and CNT� i.e. cancer tissue may contain 
some proportion of normal cells� and vice versa. Note-
wort�y� RE of t�e PLAU gene were frequently decreased 
in carcinomas� compared wit� t�e paired CNT samples. 
T�is s�ould be validated on t�e larger groups of patients 
as well. No correlation was found between RE and Gl and/
or PSA level. No significant differences of RE alteration fre-
quencies was detected in carcinomas wit� Gl ≤ � and > �� 
in contrast wit� comparison of adenomas and carcinomas 
wit� Gl ≤ � for FOS and EFNA5 genes. RE of t�e FOS gene 
were frequently increased in carcinomas wit� Gl ≤ � com-
pared wit� adenomas. RE of t�e EFNA5 gene were altered 
in t�e majority of cases �bot�� decreased and increased� 
in t�e same comparison groups. T�e investigation of t�e 
possible molecular mec�anisms of t�e involvement of t�e 
FOS and EFNA5 in prostate cancer pat�ogenesis requires 
t�e furt�er experimental work. A nonparametric regres-
sion analysis �as s�own t�e significant correlation of t�e 
increased RE level of IL1B in carcinomas compared wit� 
CNT and t�e PSA level t�at may be used as an additional 
risk factor for t�e patients wit� intermediate risk of bio-
c�emical recurrence. However� t�is s�ould be validated 
on t�e larger patient groups.
Summarizing� results of t�e present work correspond 
to t�e earlier findings� obtained wit� cell lines [8� �]. Cur-
rently� we found t�e significant c�anges in RE for 5 out 
of � genes� comparing malignant and non-malignant 
prostate tissues� namely for EFNA5� FOS� IL1B� PLAU� 
and TGFB1. T�us� t�e PLAU gene is expressed at t�e 
lower levels in carcinomas� compared wit� t�e paired 
CNT� w�ic� is in agreement wit� our data on LNCaP and 
DU�45� compared wit� PNT� cells.
CONCLUSION
In t�e present work we �ave found t�e significant 
alterations in t�e RE levels of t�e FOS� EFNA5� IL1B, 
and TGFB1 genes in prostate tumors� comparing 
to CNT. We �ave found t�at FOS and EFNA5 were more 
frequently overexpressed in carcinomas wit� Gl ≤ �� 
compared wit� adenomas. On contrary� PLAU expres-
Experimental Oncology ��� �������� ���� �June� ���
sion levels were decreased more frequently in prostate 
cancers� compared wit� CNT. Notewort�y� we found 
positive correlation between IL1B expression level and 
PSA for patients wit� slig�t PSA increase. T�e EFNA5� 
FOS� IL1B� PLAU, and TGFB1 genes t�at s�owed 
significant expression alterations in prostate tumors� 
compared wit� CNT� may play role in prostate cancer 
development and s�ould be furt�er investigated.
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